Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
20. Juli 2021 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Presents Highlights from EHA During Corporate Update Event
11. Juni 2021 07:55 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
01. Juni 2021 16:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Hold Corporate Update Friday, June 11th
27. Mai 2021 07:30 ET
|
Aptose Biosciences, Inc.
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual...
Aptose to Present at Upcoming Investor Conferences
12. Mai 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the First Quarter 2021
04. Mai 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 4:30 pm EDT today - - Luxeptinib Phase 1 a/b studies in AML and B cell malignancies continue dose escalation - - APTO-253 Phase 1 a/b study in AML / MDS advances to...
Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
26. April 2021 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
08. April 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Reports Results for the Fourth Quarter and Full Year 2020
23. März 2021 16:01 ET
|
Aptose Biosciences, Inc.
- Conference call and webcast at 5pm EDT today - - Company announces resignation of CFO Gregory Chow - - Luxeptinib (CG-806) continues dose escalation and evidence of clinical activity - SAN DIEGO...
Aptose Expands Senior Leadership Team
16. März 2021 07:30 ET
|
Aptose Biosciences, Inc.
George Melko, Pharm.D. joins as Vice President, Regulatory Affairs Robert Killion, Ph.D. appointed Vice President, CMC SAN DIEGO and TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Aptose...